Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

21 May 2024

Abstract excerpt

Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention over the last 10 years, representing a burgeoning therapeutic approach with the potential to address pathogenic proteins that have historically posed challenges for traditional small-molecule inhibitors. PROTACs exploit the endogenous E3 ubiquitin ligases to facilitate degradation of the proteins of interest (POIs) through the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38773495
DOI: 10.1186/s12943-024-02024-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New-generation advanced PROTACs as potential therapeutic agents in cancer therapyPMID 38773495Read ↗

Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity Read ↗

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Semantic proximity Read ↗

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read ↗

Proteolysis‐targeting chimeras in drug development: A safety perspectiveSemantic proximity Read ↗

Overcoming Cancer Drug Resistance Utilizing PROTAC TechnologySemantic proximity Read ↗

Clinical Translation of Targeted Protein DegradersSemantic proximity Read ↗

Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACsSemantic proximity Read ↗

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule InhibitorsSemantic proximity Read ↗

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat CancerSemantic proximity Read ↗

CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical ApplicationsSemantic proximity Read ↗

Progress of small molecules for targeted protein degradation: PROTACs and other technologiesSemantic proximity Read ↗

Breaking Bad Proteins – Discovery Approaches and the Road to Clinic for DegradersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.